ARVINAS, INC. Operating Expenses
ARVINAS, INC. (ARVN) reported Operating Expenses of $85.60 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-04
- ARVINAS, INC. operating expenses for the quarter ending 2026-06-30 was $85.60M, a 8.84% decline year-over-year.
- ARVINAS, INC. operating expenses for the quarter ending 2026-03-31 was $79.40M, a 32.37% decline year-over-year.
- ARVINAS, INC. operating expenses for the quarter ending 2025-12-31 was $84.10M, a 28.36% decline year-over-year.
- ARVINAS, INC. operating expenses for the quarter ending 2025-09-30 was $85.70M, a 47.33% decline year-over-year.
- ARVINAS, INC. operating expenses for fiscal 2025 was $381.10M, a 25.80% decline from fiscal 2024.
- ARVINAS, INC. operating expenses for fiscal 2024 was $513.60M, a 7.00% increase from fiscal 2023.
- ARVINAS, INC. operating expenses for fiscal 2023 was $480.00M, a 21.64% increase from fiscal 2022.
- ARVINAS, INC. operating expenses for fiscal 2022 was $394.60M, a 63.06% increase from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 3 month as first filed | Operating Expenses 6 month | Operating Expenses 6 month as first filed | Operating Expenses 9 month | Operating Expenses 9 month as first filed | Operating Expenses 12 month | Operating Expenses 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $85.60M 10-Q · filed 2026-08-04 | $165.00M 10-Q · filed 2026-08-04 | $249.10M derived: sum of 3 quarters · filed 2026-08-04 | $334.80M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2026-03-31 | $79.40M 10-Q · filed 2026-05-11 | $163.50M derived: sum of 2 quarters · filed 2026-05-11 | $249.20M derived: sum of 3 quarters · filed 2026-05-11 | $343.10M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-12-31 | $84.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $169.80M derived: sum of 2 quarters · filed 2026-02-24 | $263.70M derived: sum of 3 quarters · filed 2026-08-04 | $381.10M 10-K · filed 2026-02-24 | ||||
| 2025-09-30 | $85.70M 10-Q · filed 2025-11-05 | $179.60M derived: sum of 2 quarters · filed 2026-08-04 | $297.00M 10-Q · filed 2025-11-05 | $414.40M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-06-30 | $93.90M 10-Q · filed 2026-08-04 | $211.30M 10-Q · filed 2026-08-04 | $328.70M derived: sum of 3 quarters · filed 2026-08-04 | $491.40M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-03-31 | $117.40M 10-Q · filed 2026-05-11 | $234.80M derived: sum of 2 quarters · filed 2026-05-11 | $397.50M derived: sum of 3 quarters · filed 2026-05-11 | $522.50M derived: sum of 4 quarters · filed 2026-05-11 | ||||
| 2024-12-31 | $117.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $280.10M derived: sum of 2 quarters · filed 2026-02-24 | $405.10M derived: sum of 3 quarters · filed 2026-02-24 | $513.60M 10-K · filed 2026-02-24 | ||||
| 2024-09-30 | $162.70M 10-Q · filed 2025-11-05 | $287.70M derived: sum of 2 quarters · filed 2025-11-05 | $396.20M 10-Q · filed 2025-11-05 | $518.50M derived: sum of 4 quarters · filed 2026-02-24 | ||||
| 2024-06-30 | $125.00M 10-Q · filed 2025-08-06 | $233.60M 10-Q · filed 2025-08-06 | $355.80M derived: sum of 3 quarters · filed 2026-02-24 | $464.30M derived: sum of 4 quarters · filed 2026-02-24 | ||||
| 2024-03-31 | $108.60M 10-Q · filed 2025-05-01 | $230.80M derived: sum of 2 quarters · filed 2026-02-24 | $339.30M derived: sum of 3 quarters · filed 2026-02-24 | $468.40M derived: sum of 4 quarters · filed 2026-02-24 | ||||
| 2023-12-31 | $122.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $230.70M derived: sum of 2 quarters · filed 2026-02-24 | $359.80M derived: sum of 3 quarters · filed 2026-02-24 | $480.00M 10-K · filed 2026-02-24 | ||||
| 2023-09-30 | $108.50M 10-Q · filed 2024-10-30 | $237.60M derived: sum of 2 quarters · filed 2024-10-30 | $357.80M 10-Q · filed 2024-10-30 | $471.20M derived: sum of 4 quarters · filed 2025-02-11 | ||||
| 2023-06-30 | $129.10M 10-Q · filed 2024-07-30 | $249.30M 10-Q · filed 2024-07-30 | $362.70M derived: sum of 3 quarters · filed 2025-02-11 | $460.20M derived: sum of 4 quarters · filed 2025-02-11 | ||||
| 2023-03-31 | $120.20M 10-Q · filed 2024-05-07 | $233.60M derived: sum of 2 quarters · filed 2025-02-11 | $331.10M derived: sum of 3 quarters · filed 2025-02-11 | $430.70M derived: sum of 4 quarters · filed 2025-02-11 | ||||
| 2022-12-31 | $113.40M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-11 | $210.90M derived: sum of 2 quarters · filed 2025-02-11 | $310.50M derived: sum of 3 quarters · filed 2025-02-11 | $394.60M 10-K · filed 2025-02-11 | ||||
| 2022-09-30 | $97.50M 10-Q · filed 2023-11-07 | $197.10M derived: sum of 2 quarters · filed 2023-11-07 | $281.20M 10-Q · filed 2023-11-07 | $362.00M derived: sum of 4 quarters · filed 2024-02-27 | ||||
| 2022-06-30 | $99.60M 10-Q · filed 2023-08-08 | $183.70M 10-Q · filed 2023-08-08 | $264.50M derived: sum of 3 quarters · filed 2024-02-27 | $321.10M derived: sum of 4 quarters · filed 2024-02-27 | ||||
| 2022-03-31 | $84.20M 10-Q · filed 2023-05-05 | $164.90M derived: sum of 2 quarters · filed 2024-02-27 | $221.50M derived: sum of 3 quarters · filed 2024-02-27 | $278.90M derived: sum of 4 quarters · filed 2024-02-27 | ||||
| 2021-12-31 | $80.70M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $137.30M derived: sum of 2 quarters · filed 2024-02-27 | $194.70M derived: sum of 3 quarters · filed 2024-02-27 | $242.00M 10-K · filed 2024-02-27 | ||||
| 2021-09-30 | $56.60M 10-Q · filed 2022-11-09 | $56.62M 10-Q · filed 2021-11-03 | $114.00M derived: sum of 2 quarters · filed 2022-11-09 | $161.30M 10-Q · filed 2022-11-09 | $161.22M 10-Q · filed 2021-11-03 | $206.67M derived: sum of 4 quarters · filed 2023-02-23 | ||
| 2021-06-30 | $57.40M 10-Q · filed 2022-08-04 | $57.42M 10-Q · filed 2021-08-05 | $104.60M 10-Q · filed 2022-08-04 | $104.61M 10-Q · filed 2021-08-05 | $150.07M derived: sum of 3 quarters · filed 2023-02-23 | $189.42M derived: sum of 4 quarters · filed 2023-02-23 | ||
| 2021-03-31 | $47.20M 10-Q · filed 2022-05-05 | $47.19M 10-Q · filed 2021-05-04 | $92.67M derived: sum of 2 quarters · filed 2023-02-23 | $132.02M derived: sum of 3 quarters · filed 2023-02-23 | $164.25M derived: sum of 4 quarters · filed 2023-02-23 | |||
| 2020-12-31 | $45.47M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $84.82M derived: sum of 2 quarters · filed 2023-02-23 | $117.05M derived: sum of 3 quarters · filed 2023-02-23 | $146.70M 10-K · filed 2023-02-23 | $146.66M 10-K · filed 2021-03-01 | |||
| 2020-09-30 | $39.34M 10-Q · filed 2021-11-03 | $71.58M derived: sum of 2 quarters · filed 2021-11-03 | $101.23M 10-Q · filed 2021-11-03 | $128.91M derived: sum of 4 quarters · filed 2021-11-03 | ||||
| 2020-06-30 | $32.23M 10-Q · filed 2021-08-05 | $61.88M 10-Q · filed 2021-08-05 | $89.57M derived: sum of 3 quarters · filed 2021-08-05 | $114.11M derived: sum of 4 quarters · filed 2021-08-05 | ||||
| 2020-03-31 | $29.65M 10-Q · filed 2021-05-04 | $57.33M derived: sum of 2 quarters · filed 2021-05-04 | $81.88M derived: sum of 3 quarters · filed 2021-05-04 | $104.32M derived: sum of 4 quarters · filed 2021-05-04 | ||||
| 2019-12-31 | $27.68M 10-K · filed 2020-03-16 | $52.23M derived: sum of 2 quarters · filed 2020-11-05 | $74.67M derived: sum of 3 quarters · filed 2020-11-05 | $94.50M 10-K · filed 2022-02-28 | $94.50M 10-K · filed 2020-03-16 | |||
| 2019-09-30 | $24.55M 10-Q · filed 2020-11-05 | $46.99M derived: sum of 2 quarters · filed 2020-11-05 | $66.82M 10-Q · filed 2020-11-05 | $87.20M derived: sum of 4 quarters · filed 2020-11-05 | ||||
| 2019-06-30 | $22.44M 10-Q · filed 2020-08-04 | $42.27M 10-Q · filed 2020-08-04 | $62.66M derived: sum of 3 quarters · filed 2020-08-04 | $80.09M derived: sum of 4 quarters · filed 2020-08-04 | ||||
| 2019-03-31 | $19.83M 10-Q · filed 2020-04-28 | $40.21M derived: sum of 2 quarters · filed 2020-04-28 | $57.65M derived: sum of 3 quarters · filed 2020-04-28 | $69.57M derived: sum of 4 quarters · filed 2020-04-28 | ||||
| 2018-12-31 | $20.38M 10-K · filed 2020-03-16 | $37.82M derived: sum of 2 quarters · filed 2020-03-16 | $49.74M derived: sum of 3 quarters · filed 2020-03-16 | $58.13M 10-K · filed 2021-03-01 | ||||
| 2018-09-30 | $17.43M 10-K · filed 2020-03-16 | $29.35M derived: sum of 2 quarters · filed 2020-03-16 | $37.74M 10-Q · filed 2019-11-04 | $45.62M derived: sum of 4 quarters · filed 2020-03-16 | ||||
| 2018-06-30 | $11.92M 10-K · filed 2020-03-16 | $20.31M 10-Q · filed 2019-08-05 | $28.19M derived: sum of 3 quarters · filed 2020-03-16 | $36.27M derived: sum of 4 quarters · filed 2020-03-16 | ||||
| 2018-03-31 | $8.39M 10-K · filed 2020-03-16 | $16.27M derived: sum of 2 quarters · filed 2020-03-16 | $24.35M derived: sum of 3 quarters · filed 2020-03-16 | $32.74M derived: sum of 4 quarters · filed 2020-03-16 | ||||
| 2017-12-31 | $7.88M 10-K · filed 2019-03-26 | $15.96M derived: sum of 2 quarters · filed 2019-03-26 | $24.35M derived: sum of 3 quarters · filed 2019-03-26 | $32.34M 10-K · filed 2019-03-26 | ||||
| 2017-09-30 | $8.08M 10-K · filed 2019-03-26 | $16.47M derived: sum of 2 quarters · filed 2019-03-26 | $24.46M 10-Q · filed 2018-11-14 | |||||
| 2017-06-30 | $8.39M 10-K · filed 2019-03-26 | $16.38M derived: sum of 2 quarters · filed 2019-03-26 | ||||||
| 2017-03-31 | $7.99M 10-K · filed 2019-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |